Search results
Results from the WOW.Com Content Network
Dapagliflozin, sold under the brand names Farxiga (US) and Forxiga (EU) among others, is a medication used to treat type 2 diabetes. [ 6 ] [ 7 ] [ 10 ] It is also used to treat adults with heart failure and chronic kidney disease .
Dapagliflozin, (brand name Forxiga), was approved by the EU in 2012, the first SGLT2 inhibitor approved anywhere. [28] It was approved for use in the United States under the brand name Farxiga in January 2014. [29] Empagliflozin, approved in the United States in August 2014, under the brand name Jardiance by Boehringer Ingelheim. [30]
Alzheimer's disease (AD) is a neurodegenerative disease that usually starts slowly and progressively worsens. [2] It is the cause of 60–70% of cases of dementia. [2] [15] The most common early symptom is difficulty in remembering recent events. [1]
Similar to the NINCDS-ADRDA Alzheimer's Criteria are the DSM-IV-TR criteria published by the American Psychiatric Association. [3] At the same time the advances in functional neuroimaging techniques such as PET or SPECT that have already proven their utility to differentiate Alzheimer's disease from other possible causes, [4] have led to proposals of revision of the NINCDS-ADRDA criteria that ...
Some 4% of U.S. adults aged 65 and older say they have been diagnosed with dementia, a rate that reached 13% for those at least 85-years old, according to a report of a national survey released on ...
The idea of a collaboration between public institutions and private pharmaceutical companies to fund a large biomarker project to study AD and to speed up progress toward effective treatments for the disease was conceived at the beginning of the millennium by Neil S. Buckholz at the National Institute on Aging (NIA) and Dr. William Potter, at Eli Lilly and Company. [1]
Alzheimer's disease (AD) is a chronic neurodegenerative disease that results in the loss of neurons and synapses in the cerebral cortex and certain subcortical structures, resulting in gross atrophy of the temporal lobe, parietal lobe, and parts of the frontal cortex and cingulate gyrus. [14]
Almost every older patient has trouble remembering people’s names, Newhouse said. “I think it’s by far the most universal complaint of every person as they age,” Newhouse said.